Oral Microbiome and Host Inflammatory Pathways (None)

The oral microbiome and host inflammatory pathways represent a complex, bidirectional relationship between the diverse microbial community in the oral cavity and the host's immune system. In a healthy state, the oral microbiota exists in symbiosis with the host; however, dysbiosis—characterized by an overgrowth of pathobionts such as Porphyromonas gingivalis—triggers chronic inflammatory responses (Lamont et al., 2018). These pathways involve the activation of pattern recognition receptors (PRRs) like Toll-like receptors (TLRs), which stimulate the production of pro-inflammatory cytokines and matrix metalloproteinases that degrade periodontal tissues. Beyond local destruction, this axis is a significant driver of systemic inflammation, as oral bacteria and their metabolic products (e.g., lipopolysaccharides) can enter the bloodstream, contributing to the pathogenesis of chronic conditions including cardiovascular disease, diabetes, and rheumatoid arthritis (Hajishengallis, 2015). Therapeutic interventions typically focus on either mechanical/chemical reduction of the microbial biofilm or pharmacological modulation of the host's inflammatory cascade to prevent tissue damage and systemic sequelae (Genco & Sanz, 2020).

Other names

Oral-systemic axisOral dysbiosis-inflammation axisPeriodontal-inflammatory linkOral-gut-liver axisHost-microbe interactome

Therapeutic strategies involve the mechanical or chemical reduction of pathogenic microbial biofilms, stabilization of the commensal flora through probiotics, and the pharmacological inhibition of host-derived inflammatory mediators. Specifically, sub-antimicrobial doses of doxycycline inhibit matrix metalloproteinases (MMPs) to prevent tissue degradation (Genco & Sanz, 2020), while systemic biologics targeting TNF-alpha or IL-6 modulate the overactive host immune response triggered by oral dysbiosis (Hajishengallis, 2015).